Brexpiprazole (Synonyms: 依匹哌唑; OPC-34712)
目录号: PL14287 纯度: ≥99%
CAS No. :913611-97-9
商品编号 规格 价格 会员价 是否有货 数量
PL14287-5mg 5mg ¥680.00 请登录
PL14287-10mg 10mg ¥865.45 请登录
PL14287-50mg 50mg ¥1483.64 请登录
PL14287-100mg 100mg ¥2225.45 请登录
PL14287-200mg 200mg ¥3709.09 请登录
PL14287-500mg 500mg ¥6676.36 请登录
PL14287-1g 1g 询价 询价
PL14287-5g 5g 询价 询价
PL14287-10mM*1mLinDMSO 10mM*1mLinDMSO ¥748.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Brexpiprazole
中文别名
依匹唑哌;依匹唑派;7-[4-(4-苯并[b]噻吩-4-基-1-哌嗪)丁氧基]-2(1h)-喹啉酮;Brexpiprazole 抑制剂;瑞替加滨;依匹哌唑;依匹唑哌杂质;依匹唑派杂质
英文名称
Brexpiprazole
英文别名
Brexpiprazole;7-(4-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one;7-?[4-?(4-?benzo[b]?thien-?4-?yl-?1-?piperazinyl)?butoxy]?-2(1H)?-?Quinolinone;7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one;OPC 34712;OPC-34712;UNII-2J3YBM1K8C;2J3YBM1K8C;AK171366;Rexulti;Brexpiprazole [USAN:INN];Rxulti;Rexulti (TN);Brexpiprazole.2H2O;7-(4-(4-(1-Benzothiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one;Brexpiprazole(OPC34712);GTPL7672;Brexpiprazole (JAN/USAN/INN);7-[4-(4-Benzo[b]thien-4-yl-1-piperazinyl)butoxy]-2(1H)-quinolinone (ACI);7-[4-(4-(Benzo[b]thien-4-yl)-piperazin-1-yl)butoxy]-1H-quinolin-2-one
Cas No.
913611-97-9
分子式
C25H27N3O2S
分子量
433.57
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
Brexpiprazole (OPC-34712),一种非典型的、具有口服活性的抗精神紊乱剂,是人 5-HT1A 和多巴胺受体(dopamine D2L receptor)的部分激动剂,Ki 分别为 0.12 nM 和 0.3 nM。Brexpiprazole 也是 5-HT2A 受体的拮抗剂,Ki 为 0.47 nM。Brexpiprazole 对人去甲肾上腺素能受体 α1B (Ki=0.17 nM) 和 α2C (Ki=0.59 nM) 也显示出强效拮抗活性。
生物活性
Brexpiprazole (OPC-34712), an atypical orally active antipsychotic drug, is a partial agonist of human 5-HT1A and dopamine D 2L receptor with K i s of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a K i of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α 1B (K i =0.17 nM) and α 2C receptors (K i =0.59 nM).
性状
Solid
IC50 & Target[1][2]
5-HT1A Receptor 0.12 nM (Ki) 5-HT2A Receptor
体外研究(In Vitro)
Brexpiprazole (0-1.0 μM, 4 days) potentiates NGF-induced neurite outgrowth in a dose-dependent manner in PC12 cells. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Brexpiprazole (0-0.1 mg/kg; p.o.; once) improves social recognition deficits in mice. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6NCrSlc mice, Dizocilpine (0.1 mg/kg)
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Ishima T, et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 2015 Apr;25(4):505-11.
[2]. Yoshimi N, et al. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015 Mar;25(3):356-64.
溶解度数据
In Vitro: DMSO : 25 mg/mL (57.66 mM; ultrasonic and warming and heat to 80°C)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2